The Asia Pacific veterinary clinical trials market size is expected to reach USD 1,616.85 million by 2032, exhibiting a compound annual growth rate (CAGR) of 10.2% during the forecast period 2024 – 2032.
The Asia Pacific veterinary clinical trials market is gaining momentum, driven by advancements in veterinary science, increased pet adoption, and the rising demand for innovative animal healthcare solutions. This market plays a crucial role in the development of safe and effective veterinary products, including drugs, vaccines, and diagnostics, ensuring animal well-being and public health.
Download Free Sample PDF Copy of the Report:
Market Overview
The Asia Pacific region represents a significant segment of the global veterinary clinical trials market due to its expanding livestock and companion animal population. The market is characterized by:
- Growing Demand for Veterinary Pharmaceuticals: Rising incidences of zoonotic diseases and the need for improved livestock productivity are fueling demand.
- Expansion of Veterinary Research Facilities: Increased government and private sector investment in veterinary research infrastructure.
- Emergence of Regional Contract Research Organizations (CROs): A surge in partnerships and collaborations for clinical trials within the region.
Key companies in the Asia Pacific veterinary clinical trials market include
- Alembic
- Bioagile Therapeutics Pvt. Ltd.
- Boehringer Ingelheim International GmbH.
- Century Pharmaceuticals Ltd.
- Indian Immunologicals Ltd
- Knoell
- Labcorp Drug Development
- Merck & Co., Inc.
- Venkys India
- Vetnation Pharma
Market Growth Drivers
Several factors are contributing to the robust growth of the Asia Pacific veterinary clinical trials market:
- Rise in Pet Ownership: The increase in disposable incomes and changing lifestyles have led to a surge in pet adoption, boosting the need for advanced veterinary care.
- Government Support and Funding: Policies promoting animal welfare and research funding for zoonotic disease control.
- Technological Advancements: Innovations in clinical trial methodologies, including digital monitoring and AI-based data analysis.
- Livestock Industry Growth: The rising demand for meat and dairy products encourages better livestock health management.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include animal type, intervention, end use and indication. The splitting of the market into various groups enables businesses to understand market preferences and trends better
Asia Pacific Veterinary Clinical Trials Market, Animal Type Outlook (Revenue – USD Million, 2019-2032)
- Livestock Animal
- Companion Animal
- Other Animals
Asia Pacific Veterinary Clinical Trials Market, Intervention Outlook (Revenue – USD Million, 2019-2032)
- Medicines
- Medical Device
- Others
Asia Pacific Veterinary Clinical Trials Market, End User Outlook (Revenue – USD Million, 2019-2032)
- Academics And Research Centers
- Pharmaceutical And Biopharmaceutical Companies
- Others
Asia Pacific Veterinary Clinical Trials Market, Indication Outlook (Revenue – USD Million, 2019-2032)
- Orthopedics
- Oncology
- Cardiology
- Ophthalmology
- Neurology
- Dermatology
- Internal Medicine
- Other Indications
Key Market Trends
The market is witnessing several noteworthy trends:
- Precision Medicine for Animals: Tailored treatments based on genetic and environmental factors.
- Integration of Big Data in Trials: Enhanced data collection and analysis using IoT and AI.
- Rise in Preventive Veterinary Medicine: Focus on vaccines and preventive treatments to curb disease outbreaks.
- Increase in Multi-Species Trials: Expansion of trials across various animal species, ensuring broader product applicability.
Research Scope
The scope of research within the Asia Pacific veterinary clinical trials market is extensive, addressing:
- Preclinical and Clinical Development: Assessing safety, efficacy, and pharmacokinetics of veterinary products.
- Regulatory Framework Analysis: Understanding country-specific guidelines and approvals.
- Economic Impact Studies: Evaluating cost-effectiveness and market viability of veterinary innovations.
- Epidemiological Research: Studying disease patterns to guide therapeutic developments.
Future Outlook
The future of the Asia Pacific veterinary clinical trials market appears promising, underpinned by:
- Increased Collaboration: Partnerships between veterinary research institutes, CROs, and pharmaceutical companies to accelerate innovation.
- Regulatory Harmonization: Standardized guidelines across countries to streamline trials and product launches.
- Expansion of Clinical Trials in Emerging Markets: Focus on countries like India, China, and Southeast Asia due to their burgeoning animal healthcare needs.
- Sustainability Initiatives: Incorporating eco-friendly practices in veterinary research and trials.
Recent Developments in the Veterinary Clinical Trials Industry
October 2023: EQT’s Acquisition of VetPartners
EQT, through its BPEA Private Equity Fund VIII, agreed to acquire VetPartners, a leading provider of veterinary and animal health services in Australia and New Zealand, with a growing presence in Singapore. VetPartners operates a network of 267 general practice clinics and specialty hospitals, employing over 1,300 veterinarians and 3,000 nurses and clinical support staff. This acquisition aims to enhance VetPartners’ capabilities by investing in diagnostic equipment, technology, innovation, recruitment, and professional development, ultimately benefiting pets and their owners.
September 2022: SK Telecom’s Launch of ‘X Caliber’
SK Telecom introduced ‘X Caliber,’ South Korea’s first AI-based veterinary X-ray image diagnosis assistance service. Developed using data augmentation technology to enhance data diversity and AI performance, ‘X Caliber’ analyzes X-ray images of dogs and cats within approximately 15 seconds, aiding veterinarians in swift and accurate diagnoses. The service utilizes cloud technology for data storage and retrieval, eliminating the need for on-site servers and allowing veterinarians to access diagnostic results on mobile devices or PCs anytime, anywhere.
January 2020: Ceva Animal Health’s Vaccine Development Initiatives
Ceva Animal Health entered into several agreements to develop new vaccine solutions tailored to the needs of Vietnamese livestock producers. These initiatives focus on creating alternatives to antibiotics, addressing the growing concern of antibiotic resistance, and promoting sustainable livestock farming practices.
These developments reflect the veterinary industry’s commitment to advancing animal healthcare through strategic acquisitions, technological innovation, and the development of sustainable treatment solutions.
The Asia Pacific veterinary clinical trials market involves controlled studies to assess the safety and efficacy of new treatments for animals, which is crucial for advancing veterinary medicine. It supports innovation and ensures safe therapies for animals. The growing adoption of animals is a major factor propelling the Asia-Pacific veterinary clinical trials market. Additionally, increasing awareness about animal healthcare is driving the growth of the market revenue.